PMID- 29468559
OWN - NLM
STAT- MEDLINE
DCOM- 20180827
LR  - 20201027
IS  - 1179-6901 (Electronic)
IS  - 1174-5886 (Print)
IS  - 1174-5886 (Linking)
VI  - 18
IP  - 1
DP  - 2018 Mar
TI  - 15 Years of Experience with Biphasic Insulin Aspart 30 in Type 2 Diabetes.
PG  - 27-39
LID - 10.1007/s40268-018-0228-x [doi]
AB  - Since clinical experience with biphasic insulin aspart 30 (BIAsp 30) in type 2 
      diabetes mellitus (T2DM) was reviewed in 2012 after 10 years of use worldwide, 
      additional studies have been published that highlight new aspects, including use 
      in real-world populations. Evidence from 35 new studies confirms and builds upon 
      previous work indicating that BIAsp 30 continues to have pharmacodynamic and 
      clinical advantages over biphasic human insulin (BHI 30), including in real-world 
      practice with unselected populations of patients. BIAsp 30 has also been shown to 
      be safe and efficacious as an add-on to dipeptidyl peptidase-4 (DPP-4) 
      inhibitors. Intensification with BIAsp 30 is a safe and effective way to improve 
      glycemic control, and titration performed by patients can achieve results that 
      are at least comparable to those when being guided by healthcare providers. 
      Stepwise intensification using BIAsp 30 is comparable to intensification using a 
      basal-bolus regimen, and twice-daily BIAsp 30 provides similar glycemic control 
      to a basal-plus regimen. Data from large observational studies, in particular, 
      have identified patient-related characteristics that are associated with improved 
      clinical responses, suggesting that earlier initiation and intensification of 
      therapy is warranted. Finally, new health-economic analyses continue to confirm 
      that BIAsp 30 is cost effective versus other therapies such as BHI 30, neutral 
      protamine Hagedorn (NPH), or insulin glargine in both insulin-naive and 
      insulin-experienced patients. After 15 years of clinical use worldwide, analysis 
      of more recent 5-year data indicates that BIAsp 30 remains a safe, effective, and 
      simple-to-use insulin for initiation and intensification by diabetes specialists 
      and primary care physicians in a variety of patients with T2DM.
FAU - Liebl, Andreas
AU  - Liebl A
AUID- ORCID: 0000-0002-6911-4298
AD  - Department for Internal Medicine, Center for Diabetes and Metabolism, 
      m&i-Fachklinik Bad Heilbrunn, Woernerweg 30, 83670, Bad Heilbrunn, Germany. 
      andreas.liebl@fachklinik-bad-heilbrunn.de.
FAU - Mohan, Viswanathan
AU  - Mohan V
AD  - Dr. Mohan's Diabetes Specialties Centre and Madras Diabetes Research Foundation, 
      Chennai, India.
FAU - Yang, Wenying
AU  - Yang W
AD  - China-Japan Friendship Hospital, Beijing, China.
FAU - Strojek, Krzysztof
AU  - Strojek K
AD  - Department of Internal Diseases Diabetology and Cardiometabolic Diseases, SMDZ in 
      Zabrze, Medical University of Silesia, Katowice, Poland.
FAU - Linjawi, Sultan
AU  - Linjawi S
AD  - Coffs Endocrine and Diabetes Services, Coffs Harbour, NSW, 2450, Australia.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - New Zealand
TA  - Drugs R D
JT  - Drugs in R&D
JID - 100883647
RN  - 0 (Biphasic Insulins)
RN  - 0 (Dipeptidyl-Peptidase IV Inhibitors)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (insulin aspart, insulin aspart protamine drug combination 30:70)
RN  - 53027-39-7 (Insulin, Isophane)
RN  - D933668QVX (Insulin Aspart)
SB  - IM
MH  - Biphasic Insulins/adverse effects/pharmacokinetics/*therapeutic use
MH  - Cost-Benefit Analysis
MH  - Diabetes Mellitus, Type 2/*drug therapy/economics
MH  - Dipeptidyl-Peptidase IV Inhibitors/therapeutic use
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Hypoglycemic Agents/adverse effects/economics/therapeutic use
MH  - Insulin Aspart/adverse effects/pharmacokinetics/*therapeutic use
MH  - Insulin, Isophane/adverse effects/pharmacokinetics/*therapeutic use
PMC - PMC5833912
COIS- AL has received funding for membership on Novo Nordisk and Eli Lilly advisory 
      boards and/or consulting services and for lectures from Novo Nordisk, Eli Lilly, 
      Sanofi, Boehringer-Ingelheim, AstraZeneca, Roche, and MSD. VM has received 
      research grants and honoraria from Novo Nordisk, Sanofi, MSD, Johnson & Johnson, 
      and Eli Lilly and lecture fees from Novo Nordisk. WY has attended advisory boards 
      and been a speaker for Novo Nordisk. KS has received honoraria for speaking 
      engagements from Eli Lilly, Novo Nordisk, Sanofi-Aventis, Servier, 
      Boehringer-Ingelheim, and Polfa-Tarchomin and has participated in clinical trials 
      for AstraZeneca, Pfizer, and Amgen. SL has received funding for advisory 
      activities from Novo Nordisk and for speaker activities from Novo Nordisk, 
      Novartis Pharma AG, Roche Pharmaceuticals, and AstraZeneca Pharmaceuticals LP.
EDAT- 2018/02/23 06:00
MHDA- 2018/08/28 06:00
PMCR- 2018/02/21
CRDT- 2018/02/23 06:00
PHST- 2018/02/23 06:00 [pubmed]
PHST- 2018/08/28 06:00 [medline]
PHST- 2018/02/23 06:00 [entrez]
PHST- 2018/02/21 00:00 [pmc-release]
AID - 10.1007/s40268-018-0228-x [pii]
AID - 228 [pii]
AID - 10.1007/s40268-018-0228-x [doi]
PST - ppublish
SO  - Drugs R D. 2018 Mar;18(1):27-39. doi: 10.1007/s40268-018-0228-x.